Dr. Navid Sarwar

About Dr. Navid Sarwar

Dr Naveed Sarwar is a Consultant Medical Oncologist with extensive experience in chemotherapy, immunotherapy, endocrine therapy, and targeted therapies.
Dr Sarwar specialises in the treatment of prostate, kidney, and bladder cancers, as well as skin, breast, testicular, and gynaecological cancers.
Dr Sarwar’s approach is centred on personalising care for each patient, considering co-existing conditions, and explaining all treatment options in simple terms.
Dr Sarwar qualified from St George’s Hospital Medical School.
Dr Sarwar completed his specialist oncology training at Charing Cross Hospital, Chelsea and Westminster Hospital, and The Royal Marsden.
Dr Sarwar holds a PhD from Imperial College London.
Dr Sarwar worked for four years as a Clinical Research Fellow at Cancer Research UK.
Dr Sarwar is currently involved in clinical trials of new biological agents for breast cancer.
Dr Sarwar has published widely in peer-reviewed journals with research covering multiple cancer types.

Conditions treated by Dr. Navid Sarwar

Prostate cancer
Kidney cancer
Bladder cancer
Skin cancer
Breast cancer
Testicular cancer
Gynaecological cancer

Area of Interest

Medical oncology

Qualification

BSc in Immunology and Oncology, St George's Hospital Medical School (1993)
MBBS, St George's Hospital Medical School (1996)
MRCP Royal College of Physicians, London (2000)
PhD Imperial College London (2006)

Work Experiences

Dr Naveed Sarwar trained in oncology at Charing Cross, Chelsea & Westminster, and The Royal Marsden.
Dr Sarwar worked as a Clinical Research Fellow at Cancer Research UK for four years.
Dr Sarwar served as Lead for Urological Medical Oncology at Charing Cross Hospital.
Dr Sarwar acted as Research Lead for Urological Cancers in the NW Thames network.
Dr Sarwar held the role of Clinical Research Lead for Gynaecological Cancers in Essex.

Global Team of Board Certified Surgeons and Medical Specialists
Written Second Opinion report delivered within 5 days
Option to avail the Video Consultation with the Lead Doctor of the board

Access Our most trusted Medical Second Opinion

Telemedicine Doctors

Do you know?

You can book a video consultation with Dr. Navid Sarwar on our platform

Consult Online

CERTIFICATIONS (1)

MEMBERSHIPS (5)

Royal College of Physicians (Member)
European Society of Medical Oncology (Member)
National Testicular Cancer Clinical Study Group (Member)
British Medical Association (Member)
European Organisation for Treatment of Trophoblastic Diseases (Member)

RESEARCH PAPERS AND PUBLICATIONS (5)

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. N Engl J Med. 2019 Jul 25;381(4):338-348. doi: 10.1056/NEJMoa1817323
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, Yanez Ruiz E, Maruzzo M, Suarez Zaizar A, Fein LE, Schutz FA, Heng DYC, Wang F, Mataveli F, Chang YL, van Kooten Losio M, Suarez C, Motzer RJ; COSMIC-313 Investigators. N Engl J Med. 2023 May 11;388(19):1767-1778. doi: 10.1056/NEJMoa2212851.
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. Brown JE, Royle KL, Gregory W, Ralph C, Maraveyas A, Din O, Eisen T, Nathan P, Powles T, Griffiths R, Jones R, Vasudev N, Wheater M, Hamid A, Waddell T, McMenemin R, Patel P, Larkin J, Faust G, Martin A, Swain J, Bestall J, McCabe C, Meads D, Goh V, Min Wah T, Brown J, Hewison J, Selby P, Collinson F; STAR Investigators. Lancet Oncol. 2023 Mar;24(3):213-227. doi: 10.1016/S1470-2045(22)00793-8. Epub 2023 Feb 13

Share Your Experience about Dr. Navid Sarwar

Write Your Review

PROCEDURES

Breast Cancer Treatment
Kidney Cancer Treatment
Prostate Cancer Treatment

FREQUENTLY ASKED QUESTIONS

Is Dr. Navid Sarwar doing teleconsultation on the MediGence platform?

Dr. Navid Sarwar is available to teleconsult on the MediGence platform.

How long is the consultation?

The consultation typically lasts between 15 and 30 minutes. It may exceed the estimated time, depending on the patient’s queries and the doctor's medical suggestions.

How soon can the consultation be organised?

We have Medical specialists and board-certified doctors on our panel of doctors. The consultation will be organised within 24 to 48 hours or based on the availability of the doctor and the patient.

Is a follow-up consultation included in the consultation price?

No, the follow-up consultation fee is not included in the consultation price. The patient will be required to re-book the consultation.

How do I share my medical record with the doctor for review?

The option to share your medical records is available between the steps of the form provided to you on the website.

Can I book my procedure with the doctor after the consultation?

Yes. If you are satisfied with the consultation, you can proceed with treatment packages tailored to your diagnosis, assisted by our case managers.

Can you get an estimate for the procedure?

Yes. The cost estimate will be provided to you by our case manager, including the doctor’s opinion, the cost estimate, and crucial information about travelling to your medical destination.

FAQ's Related to Medical Oncologist

What is a medical oncologist?

A medical oncologist is a doctor who specialises in diagnosing and treating cancer using chemotherapy, immunotherapy, hormone therapy, and targeted therapies.

How is a medical oncologist different from a surgical or radiation oncologist?

A medical oncologist focuses on drug-based treatments, while surgical oncologists remove tumours through surgery and radiation oncologists treat cancer with radiation therapy.

When should a patient see a medical oncologist?

Patients are referred to a medical oncologist after a cancer diagnosis or if their case requires systemic treatments such as chemotherapy, immunotherapy, or targeted therapy.

Do medical oncologists provide personalised treatment plans?

Yes, medical oncologists tailor treatment to each patient’s cancer type, stage, health condition, and personal preferences.

Can a medical oncologist help with advanced or late-stage cancers?

Absolutely. Medical oncologists play a crucial role in managing advanced cancers by providing therapies that enhance survival, alleviate symptoms, and preserve quality of life.

Do medical oncologists work with other specialists?

Yes, they are part of a multidisciplinary team, collaborating with surgeons, radiation oncologists, radiologists, and pathologists to provide comprehensive cancer care.

Welcome To MediGence

Your Notifications